

Cell death after anti-Wnt Ab incubation (%)





FIG. 1

## Fraction of apoptotic cell death (%) after anti-Wnt antibody treatment

Cell Line	No Treatment	Control Ab	Anti-Wnt-1 Ab	Anti-Wnt-2 Ab
CCL-75 (normal lung)	0.9 ±0.3	3.8 ±2.3	5.8 ±2.1	2 ±1.1
H838 (lung cancer)	1.7 ±0.8	3.1 ±3.0	28.4 ±4.6	58.3 ±8.1
H460 (lung cancer)	0.6 ±0.3	12.7 ±7.0	83.8 ±5.6	90.7 ±6.5
A549 (lung cancer)	0.3 ±0.1	4.9 ±3.0	84.7 ±3.3	82.3 ±4.5
MCF-7 (breast cancer)	0.7 ±0.4	1.6 ±0.7	56.7 ±3.9	47.2 ±4.2
SKBR-3 (breast cancer)	0.4 ±0.1	5.8 ±1.3	67.9 ±6.1	56.4 ±4.8
SW-480 (colon cancer)	5.9 ±0.8	14.6 ±4.6	43.3 ±4.4	48.9 ±5.2
SAOS-2 (sarcoma)	1.1 ±0.4	4.2 ±1.6	20.0 ±3.2	16.5 ±1.0
LP-9 (normal mesothelial)	2.3 ±1.1	5.1 ±2.7	4.1 ±1.5	6.2 ±2.6
REN (mesothelioma)	13.6 ±2.4	15.2 ±6.5	89.6 ±3.8	81.4 ±8.4
H28 (mesothelioma)	6.6 ±3.5	12.4 ±7.4	68.7 ±5.8	41.3 ±6.6

**FIG. 2**



**FIG. 3A**






FIG. 3B




**FIG. 4A**



**FIG. 4B**

FIGURE 5






FIG. 6A






FIG. 6B



*in vivo* study on breast cancer. Tumor volume is shown after 3 weeks treatment with anti-Wnt-1 monoclonal antibody and control monoclonal antibody. 5 animals are in each group. None of the animals grows tumor after anti-Wnt-1 mAb injection, but three out of five animals grow tumor in the control group. (I.P. injection was done once weekly one week after inoculation of the MCF-7 cells)

**FIG. 6C**



*in vivo* study on breast cancer. Tumor volume is shown after 3 weeks treatment with anti-Wnt-1 monoclonal antibody and control monoclonal antibody. 5 animals are in each group. None of the animals grows tumor after anti-Wnt-1 mAb injection, but three out of five animals grow tumor in the control group. (I.P. injection was done once weekly one week after inoculation of the MCF-7 cells)

**FIG. 6C**

# Figure 7

1) CDR and FR region (light chain kappa) amino acid sequence of a anti-WNT1 antibody (Seq ID No:4)

Clone #1

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y21

1y2

1y21  
115  
T R S E G G P S \* K N G  
ACA CGT TCG GAG GGG GGA CCA AGC TGA AAA AAC GGG

clone #2

<----- F R 1 - I M G T ----->  
1 5 10 15 20  
D I V V T Q S P A S L A V S L G Q R A T I S  
1y22W11krs GAC ATT GTG GTG ACA CAG TCT CCT GCT TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA

-----> <----->  
CDR1 - IMGT  
25 30 35 40  
Y R A S K S V S T S G Y S Y M H W N Q Q  
1y22W11krs TAC AGG GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ... ATG CAC TGG AAC CAA CAG

F R 2 - I M G T -----> <----->  
CDR2 - IMGT  
45 50 55 60 65  
K P G Q P P R L L I Y L V S N  
1y22W11krs AAA CCA GGA CAG CCA CCC AGA CTC ATC TAT CTT GTA TCC ... AAC

-----> <----->  
70 75 80 85  
L E S G V P A R F S G S G S G T D F T  
1y22W11krs CTA GAA TCT GGG GTC CCT ... GCC AGG TTC AGT GGC AGT GGG ... TCT GGG ACA GAC TTC ACC

----->  
90 95 100 105 110 CDR3 - I  
L N I H P V E E E D A A T Y Y C Q H I R E L  
1y22w11krs CTC AAC ATC CAT CCT GTG GAG GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC ATT AGG GAG CTT

MGT 115 120  
S T X R R G E P S \* N K R  
1y22w11krs AGC ACG TTX CGG AGG GGG GAG CCA AGC TGA AAT AAA CGG

2) CDR and FR region (light chain kappa) amino acid sequence of a anti-WNT2 antibody (Seq ID No:9)

<----- F R I - I M G T ----->  
1 5 10 15 20  
D I V L T Q S P A S L A V S L G Q R A T I S  
1y23w21krs GAC ATT GTG CTG ACA CAG TCT CCT GCT TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA

-----> <----->  
25 30 35 40 CDR1 - IMGT  
Y R A S K S V S T S G Y S Y M H W N Q Q  
1y23w21krs TAC AGG GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ... ATG CAC TGG AAC CAA CAG

F R 2 - I M G T -----> <----->  
45 50 55 60 65 CDR2 - IMGT  
K P G Q P P R L L I Y L V S N  
1y23w21krs AAA CCA GGA CAG CCA CCC AGA CTC ATC TAT CTT GTA TCC ... AAC  
----- F R 3 - I M G T -----

70 75 80 85  
L E S R R S P A R F S G Q W C L V Y R  
1y23w21kRs CTA GAA TCT AGG AGG TCA ... CCT GCC AGG TTC AGT GGT CAG ... TGG TGT CTG GTG TAC AGA

----->  
90 95 100 105 110  
L H P Q T S M P V G G G C L Q P D Y X C S  
1y23w21kRs CTT CAC CCT CAG ACA TCC ATG CCT GTC GGA GGA GGA TGC CTG CAA CCT GAT TAT XTG TGC AGC

MGT 115 120 125  
T L G S L H V T E G G P S \* K N x  
1y23w21kRs ACA TTA GGG AGC TTA CAC GTT ACG GAG GGG GGA CCA AGC TGA AAA AAC GG

3) CDR and FR region (heavy chain IgG1) amino acid sequence of a anti-WNT1 antibody (Seq ID No:4)  
XGTTXCAGCCTGXAGGAGTCXGGTGGA...GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCTG  
GATTCACCTTTTAAATACCTACGCC.....ATGAACTGGGTCCGCCAGGCTCCAGGAAAGGTTTGGAATGGGT  
TGCTCGCATAAGAACTAGACGTTATAATTCTGCAACATATTATGCCGATTCTGTGAAA...GACAGGTTACCATCTCC  
AGAGATGATTACGGGGCATGCTCTATCTGCAAAATGAACNACTTGAAAACTGAGGACACAGCCATGTATTACTGTGTGA  
GGC

4) CDR and FR region (heavy chain IgG1) amino acid sequence of a anti-WNT2 antibody (Seq ID No:9)  
<----- F R I - I M G T -----

1y25W2HGRs 1 5 10 15 20  
x x x G P E L V K P G A S V K M S  
.AG TCX GGA CCT ... GAG CTG GTG AAG CCT GGG GCT TCA GTG AAG ATG TCC

----->> <-----

CDR1 - IMGT 30 35 40  
C K A S G Y T F T D Y V L S W V K Q  
TGC AAG GCT TCT GGA TAC ACA TTC ACT GAC TAT GTT ... TTA AGC TGG GTG AAG CAG

F R 2 - I M G T -----> <---

CDR2 - IMGT 55 60 65  
R T G Q G L E W I G E I Y P G Y G S T Y  
AGA ACT GGA CAG GGC CTT GAG TGG ATT GGA GAG ATT TAT CCT GGA TAT GGT AGT ACT ... TAC

-----> F R 3 - I M G T -----

70 75 80 85  
Y N E K F K G K A T L T A D K S S N T A Y  
TAC AAT GAG AAG TTC AAG ... GGC AAG GCC ACA CTG ACT GCT GAC AAA TCC TCC AAC ACA GCC TAC

-----> <-----

CDR3 - I 105 110  
M Q L S S L T S E D S A V Y F C A R W G D C  
ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TGG GGG GAT TGC

MGT 115 120 125  
F C L S G A K G x L V x C L C

1y25W2HGRs TTT TGC TTA TCT GGG GCC AAG GGA XCT CTG GTC AXC TGT CTC TGC

FIGURE 8




FIGURE 9




Figure 10. Over-expression of Wnt signal antagonist (FRP or DKK) induces apoptosis in cancer cell line MS-1

